Palvella Therapeutics (PVLA) Equity Average (2014 - 2026)
Palvella Therapeutics (PVLA) reported Equity Average of $130.1 million for Q1 2026, up 120.25% year-over-year from $59.1 million in Q1 2025, and up 290.45% on a QoQ basis from $33.3 million in Q4 2025.
Palvella Therapeutics (PVLA) has 13 years of Equity Average data on file, last reported at $130.1 million in Q1 2026.
- Quarterly Equity Average rose 120.25% year-over-year to $130.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $130.1 million (up 120.25% YoY) and the FY2025 annual result came in at $45.3 million, up 862.8% from the prior year.
- Equity Average improved to $130.1 million in Q1 2026 per PVLA's latest filing, from $33.3 million in the prior quarter.
- Across five years, Equity Average topped out at $130.1 million in Q1 2026 and bottomed at -$84.1 million in Q3 2024.
- The 5-year median for Equity Average is $33.3 million (2025), against an average of $11.3 million.
- The widest annual swing landed in 2024, when Equity Average plunged 381.83%; it then jumped 368.84% in 2025.
- Tracing PVLA's Equity Average over 5 years: stood at $48.9 million in 2022, then tumbled by 144.96% to -$22.0 million in 2023, then soared by 43.61% to -$12.4 million in 2024, then jumped by 368.84% to $33.3 million in 2025, then surged by 290.45% to $130.1 million in 2026.
- Per Business Quant, the three latest PVLA Equity Average figures stand at $130.1 million (Q1 2026), $33.3 million (Q4 2025), and $43.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 130.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130.15 Mn |
| Dec 31, 2025 | 33.33 Mn |
| Sep 30, 2025 | 43.23 Mn |
| Jun 30, 2025 | 51.68 Mn |
| Mar 31, 2025 | 59.09 Mn |
| Dec 31, 2024 | -12.40 Mn |
| Sep 30, 2024 | -84.12 Mn |
| Jun 30, 2024 | -78.85 Mn |
| Mar 31, 2024 | -75.68 Mn |
| Dec 31, 2023 | -21.99 Mn |
| Sep 30, 2023 | 35.50 Mn |
| Jun 30, 2023 | 27.98 Mn |
| Mar 31, 2023 | -39.16 Mn |
| Jun 30, 2022 | 48.91 Mn |
| Mar 31, 2022 | 52.10 Mn |
| Dec 31, 2021 | 52.30 Mn |
| Sep 30, 2021 | 50.29 Mn |
| Jun 30, 2021 | 42.48 Mn |
| Mar 31, 2021 | 34.63 Mn |
| Dec 31, 2020 | 37.36 Mn |
| Sep 30, 2020 | 45.18 Mn |
| Jun 30, 2020 | 48.24 Mn |
| Mar 31, 2020 | 50.58 Mn |
| Dec 31, 2019 | 36.00 Mn |
| Sep 30, 2019 | 20.06 Mn |
| Jun 30, 2019 | 24.82 Mn |
| Mar 31, 2019 | 35.05 Mn |
| Dec 31, 2018 | 45.10 Mn |
| Sep 30, 2018 | 52.79 Mn |
| Jun 30, 2018 | 53.00 Mn |
| Mar 31, 2018 | 31.11 Mn |
| Dec 31, 2017 | 8.04 Mn |
| Sep 30, 2017 | 6.95 Mn |
| Jun 30, 2017 | 13.68 Mn |
| Mar 31, 2017 | 21.63 Mn |
| Dec 31, 2016 | 28.35 Mn |
| Sep 30, 2016 | 34.39 Mn |
| Jun 30, 2016 | 32.23 Mn |
| Mar 31, 2016 | 29.15 Mn |
| Dec 31, 2015 | 32.39 Mn |
| Sep 30, 2015 | 22.40 Mn |
| Jun 30, 2015 | 12.69 Mn |
| Mar 31, 2015 | 16.12 Mn |
| Dec 31, 2014 | 9.00 Mn |
| Sep 30, 2014 | 4,555.00 |
| Jun 30, 2014 | 2,618.00 |
| Mar 31, 2014 | 290,114.50 |